| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.27 | 6e-08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.17 | 8e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.24 | 9e-07 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0004 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0007 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.15 | 0.004 |